Strong Revenue Growth
Revenue grew 45% compared to Q1 of 2024, driven by key products like Mounjaro and Zepbound, which contributed over $4 billion in growth and accounted for $7.5 billion of the company's revenue.
Phase 3 Orforglipron Trial Success
Orforglipron achieved significant results in its Phase 3 trial for Type 2 diabetes, with hemoglobin A1c reductions of 1.3% to 1.6% and weight loss of approximately 16 pounds or 7.9% body weight at the highest dose.
Manufacturing Investment Expansion
Lilly announced over $50 billion in new U.S. manufacturing investments since 2020, including plans to build four new facilities, three of which will be active pharmaceutical ingredient facilities.
Strong Performance of Mounjaro and Zepbound
Mounjaro sales were $3.8 billion, more than double the same quarter last year, and Zepbound sales increased by $1.8 billion to $2.3 billion, making it the U.S. market leader in anti-obesity prescriptions.
Strong Financial Performance Metrics
Gross margin increased to 83.5% in Q1, and the non-GAAP performance margin was 42.6%, an increase of over 11 percentage points from Q1 2024.